Real-time fMRI Neurofeedback for Mild/Moderate Depression

Sponsor
Federal Research Center of Fundamental and Translational Medicine, Russian Federation (Other)
Overall Status
Completed
CT.gov ID
NCT05025904
Collaborator
(none)
33
1
3
22.1
1.5

Study Details

Study Description

Brief Summary

The aim of the study is to compare the effects of the self-regulation (neurofeedback) of the fMRI signal of the prefrontal cortex in depression to ones of more conventional non-pharmacological treatment, primarily, psychotherapy.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Real-time fMRI neurofeedback (rt-fMRI NFB)
  • Behavioral: Сognitive behavioral therapy (CBT)
  • Behavioral: EEG neurofeedback (EEG NFB)
N/A

Detailed Description

The study was devoted to the neural, clinical, and psychological effects of the rt-fMRI neurofeedback for mild/moderate depression. Recruited unmedicated patients suffering from depression were assigned either to the fMRI neurofeedback (8 sessions of the left prefrontal cortex activity regulation) or to the active control group, i.e., a double dosage of cognitive-behavioral treatment or EEG neurofeedback (preliminary aborted). Depression symptoms were measured at baseline, at mid-treatment, and at post-treatment points. Some inventories of depression and related traits were also given. In the rt-fMRI group, self-regulation learning was also estimated by means of the fMRI signal change.

Study Design

Study Type:
Interventional
Actual Enrollment :
33 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants were assigned to one of 3 groups: real-time fMRI neurofeedback (rt-fMRI NFB), EEG neurofeedback (aborted), and cognitive behavioral therapy (CBT).Participants were assigned to one of 3 groups: real-time fMRI neurofeedback (rt-fMRI NFB), EEG neurofeedback (aborted), and cognitive behavioral therapy (CBT).
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Functional Mechanism of the Neurovascular Coupling: an fMRI-EEG Study in Depressive Depression
Actual Study Start Date :
Jun 6, 2017
Actual Primary Completion Date :
Apr 9, 2019
Actual Study Completion Date :
Apr 9, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Real-time fMRI neurofeedback (rt-fMRI NFB)

The duration of a session was approximately a half-hour. The course duration was 8 sessions. The preferred frequency was once a week, however, the schedule was flexibly adjusted for patients' convenience.

Behavioral: Real-time fMRI neurofeedback (rt-fMRI NFB)
Real-time fMRI neurofeedback targeting control of the left medial prefrontal cortex. Participants continuously received visual feedback on the level of activity within the 2D region of interest corrected to the whole-slice brain volume activity. Up- and downregulation blocks were switched for better control.

Active Comparator: Сognitive behavioral therapy (CBT)

The duration of a session was approximately an hour/hour and a half. The course duration was 8 individual and 8 group sessions and included home assignments. The preferred frequency was twice a week, however, the schedule was flexibly adjusted for patients' convenience and for improving benefits of the treatment.

Behavioral: Сognitive behavioral therapy (CBT)
A combination of individual and small-group cognitive behavioral therapy by an experienced medical psychologist and a psychiatrist.

Active Comparator: EEG neurofeedback (EEG NFB)

The duration of a session was approximately a half-hour. The course duration was 16 sessions. The preferred frequency was twice a week, however, the schedule was flexibly adjusted for patients' convenience. Group was preliminarily aborted for lack of time and participants in order to assign more patients to the abovementioned arms.

Behavioral: EEG neurofeedback (EEG NFB)
EEG neurofeedback targeting frontal alpha asymmetry index. Participants continuously received visual feedback on their frontal alpha asymmetry index. Up-regulation condition only was utilized.

Outcome Measures

Primary Outcome Measures

  1. Change in depression symptoms severity from baseline to end-treatment [4.5 months on average]

    Montgomery-Asberg Depression Rating Scale (MADRS), scores ranging 0-54, higher scores indicate more severe depression

  2. Change in depression symptoms severity from baseline to mid-treatment [2.5 months on average]

    Montgomery-Asberg Depression Rating Scale (MADRS), scores ranging 0-54, higher scores indicate more severe depression

Secondary Outcome Measures

  1. Change in subjective depression severity, test 1 from baseline to end-treatment [4.5 months on average]

    Beck Depression Inventory (BDI), scores ranging 0-63, higher scores indicate more severe subjective depression

  2. Change in subjective depression severity, test 1 from baseline to mid-treatment [2.5 months on average]

    Beck Depression Inventory (BDI), scores ranging 0-63, higher scores indicate more severe subjective depression

  3. Change in subjective depression severity, test 2 from baseline to end-treatment [4.5 months on average]

    Zung Self-Rating Depression Scale (ZSRDS), scores ranging 20-80, higher scores indicate more severe subjective depression

  4. Change in subjective depression severity, test 2 from baseline to mid-treatment [2.5 months on average]

    Zung Self-Rating Depression Scale (ZSRDS), scores ranging 20-80, higher scores indicate more severe subjective depression

  5. Change in the raw estimate of subjective depression severity from baseline to end-treatment [4.5 months on average]

    Hospital Anxiety and Depression Scale (HADS), depression subscale, scores ranging 0-21, higher scores indicate more severe subjective depression

  6. Change in the raw estimate of subjective depression severity from baseline to mid-treatment [2.5 months on average]

    Hospital Anxiety and Depression Scale (HADS), depression subscale, scores ranging 0-21, higher scores indicate more severe subjective depression

Other Outcome Measures

  1. Change in adult anxious attachment from baseline to end-treatment [4.5 months on average]

    Experience in Close Relationships (ECR), anxious attachment subscale, scores ranging 15-105, higher scores indicate more attachment disruption

  2. Change in adult anxious attachment from baseline to mid-treatment [2.5 months on average]

    Experience in Close Relationships (ECR), anxious attachment subscale, scores ranging 15-105, higher scores indicate more attachment disruption

  3. Change in adult avoidant attachment from baseline to end-treatment [4.5 months on average]

    Experience in Close Relationships (ECR), avoidant attachment subscale, scores ranging 15-105, higher scores indicate more attachment disruption

  4. Change in adult avoidant attachment from baseline to mid-treatment [2.5 months on average]

    Experience in Close Relationships (ECR), avoidant attachment subscale, scores ranging 15-105, higher scores indicate more attachment disruption

  5. Change in rumination level from baseline to end-treatment [4.5 months on average]

    Rumination Response Scale (RRS), total rumination score, scores ranging 22-88, higher scores indicate more rumination

  6. Change in rumination level from baseline to mid-treatment [2.5 months on average]

    Rumination Response Scale (RRS), total rumination score, scores ranging 22-88, higher scores indicate more rumination

  7. Change in alexithymia level from baseline to end-treatment [4.5 months on average]

    Toronto Alexithymia Scale (TAS-26), scores ranging 26-130, higher scores indicate more alexithymia

  8. Change in alexithymia level from baseline to mid-treatment [2.5 months on average]

    Toronto Alexithymia Scale (TAS-26), scores ranging 26-130, higher scores indicate more alexithymia

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • A diagnosis of unipolar depressive disorder on ICD-10 (F32, F33, F34.1)

  • Sufficient self-regulation ability (verified with 3 sessions of ALAY EEG neurofeedback)

Exclusion Criteria:
  • Serious somatic, mental, or substance abuse problem other than depression

  • Depression secondary to other mental or somatic conditions

  • Psychotic features in depression or comorbid psychotic disorder

  • Serious suicide risk

  • Seasonal depression

  • Receiving or planning to receive psychotropic medications

  • Receiving cardiovascular medications

  • General MRI exclusions

  • Current pregnancy

  • IQ<70 (established with Raven's progressive matrices)

  • Previous experience with neurofeedback

Contacts and Locations

Locations

Site City State Country Postal Code
1 Federal Reserch Center of Fundamental and Translational Medicine Novosibirsk Russian Federation 630117

Sponsors and Collaborators

  • Federal Research Center of Fundamental and Translational Medicine, Russian Federation

Investigators

  • Study Director: Mark B. Shtark, Ph.D., FRC FTM

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Federal Research Center of Fundamental and Translational Medicine, Russian Federation
ClinicalTrials.gov Identifier:
NCT05025904
Other Study ID Numbers:
  • 16-15-00183
First Posted:
Aug 27, 2021
Last Update Posted:
Aug 27, 2021
Last Verified:
Aug 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Federal Research Center of Fundamental and Translational Medicine, Russian Federation
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 27, 2021